| EIGR Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the EIGR shares outstanding history going back to 3/23/2016:
Also see: EIGR Market Cap History EIGR YTD Return |
EIGR Shares Outstanding History — Eiger BioPharmaceuticals Share Count Over Time
As of 4/4/2024 Eiger BioPharmaceuticals has 1.48 million EIGR shares outstanding. Investors often track the EIGR shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows EIGR share count trends over time, with 33 historical shares outstanding datapoints presented, dating back to 3/23/2016.
| EIGR Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EIGR Historical Shares Outstanding: +51.27% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EIGR Stock Price Chart |
| About Eiger BioPharmaceuticals Inc |
| Eiger BioPharmaceuticals is a commercial-stage biopharmaceutical company. Co.'s portfolio includes a late-stage clinical development pipeline with five clinical product candidates and one U.S. Food and Drug Administration (FDA)-approved product. Co.'s clinical product candidates include: Lonafarnib for Hepatitis Delta Virus (HDV), Peginterferon Lambda for HDV, Combination Therapy for HDV; Peginterferon Lambda (lambda) for COVID-19, Avexitide in Congenital Hyperinsulinism, and Avexitide in Post-Bariatric Hypoglycemia. Co. has received FDA approval for Zokinvy to reduce the risk of mortality in Progeria and to treat processing-deficient Progeroid Laminopathies. We show 33 historical shares outstanding datapoints in our coverage of EIGR's shares outstanding history. Understanding the changing numbers of EIGR shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EIGR versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EIGR by allowing them to research EIGR shares outstanding history as well as any other stock in our coverage universe. |
| EIGR Current Stock Quote |
Quotes delayed 20 minutes  Free EIGR Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| EIGR Share Performance |
| Shares Outstanding Peers |
| Eiger BioPharmaceuticals (EIGR) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
EKSO Shares Outstanding History ELAB Shares Outstanding History ELAN Shares Outstanding History ELDN Shares Outstanding History ELEV Shares Outstanding History ELGX Shares Outstanding History ELOX Shares Outstanding History ELTX Shares Outstanding History ELUT Shares Outstanding History ELVN Shares Outstanding History More Healthcare companies » |
EIGR Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
